Aurobindo Pharma to sell shares in Auro Vaccines to Curateq Biologics
Hyderabad: The Board of Directors of Aurobindo Pharma Limited has approved the sale and transfer of all equity shares held by the Company in Auro Vaccines Private Limited, a wholly owned subsidiary of the Company, to Curateq Biologics Private Limited, another wholly owned subsidiary of the Company, as part of verticalization of business operations.
The completion of the sale is estimated in the first quarter of FY 2023-24.
As per the Share Purchase Agreement, the entire equity share capital of Rs. 10,00,000 (divided into 1,00,000 equity shares of Rs.10 each) of Auro Vaccines Private Limited, a wholly owned subsidiary of the Company incorporated on November 8, 2021, will be transferred by the Company to Curateq Biologics Private Limited, another wholly owned subsidiary of the Company.
"The shares are proposed to be transferred at par and accordingly, the consideration is Rs. 10 lakhs for transfer of 1,00,000 equity shares of Rs.10 each," the company stated in a recent BSE filing.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.